MX357402B - Metodo para predecir el pronostico de cancer de mama. - Google Patents

Metodo para predecir el pronostico de cancer de mama.

Info

Publication number
MX357402B
MX357402B MX2014005547A MX2014005547A MX357402B MX 357402 B MX357402 B MX 357402B MX 2014005547 A MX2014005547 A MX 2014005547A MX 2014005547 A MX2014005547 A MX 2014005547A MX 357402 B MX357402 B MX 357402B
Authority
MX
Mexico
Prior art keywords
breast cancer
kif1b
level
recurrence
survival
Prior art date
Application number
MX2014005547A
Other languages
English (en)
Spanish (es)
Other versions
MX2014005547A (es
Inventor
B Baker Joffre
V Sinicropi Dominick
J Pelham Robert
Crager Michael
Collin Francois
C Stephans James
Liu Mei-Lan
Morlan John
Qu Kunbin
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2014005547A publication Critical patent/MX2014005547A/es
Publication of MX357402B publication Critical patent/MX357402B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • G01N33/57515
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MX2014005547A 2011-11-08 2012-11-02 Metodo para predecir el pronostico de cancer de mama. MX357402B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557238P 2011-11-08 2011-11-08
US201261597426P 2012-02-10 2012-02-10
PCT/US2012/063313 WO2013070521A1 (en) 2011-11-08 2012-11-02 Method of predicting breast cancer prognosis

Publications (2)

Publication Number Publication Date
MX2014005547A MX2014005547A (es) 2014-08-29
MX357402B true MX357402B (es) 2018-07-09

Family

ID=48290467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005547A MX357402B (es) 2011-11-08 2012-11-02 Metodo para predecir el pronostico de cancer de mama.

Country Status (9)

Country Link
US (4) US20140296085A1 (enExample)
EP (1) EP2776830B1 (enExample)
JP (2) JP6147755B2 (enExample)
AU (1) AU2012336120B2 (enExample)
CA (1) CA2854805C (enExample)
IL (4) IL232445B (enExample)
MX (1) MX357402B (enExample)
SG (2) SG10202010758SA (enExample)
WO (1) WO2013070521A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
EP2648762B1 (en) 2010-12-09 2018-02-21 Biotheranostics, Inc. Post-treatment breast cancer prognosis
WO2014044724A1 (en) * 2012-09-18 2014-03-27 Qiagen Gmbh Method and kit for preparing a target rna depleted sample
WO2014110230A2 (en) * 2013-01-09 2014-07-17 Health Research, Inc. Methods for diagnosing cancer based on small nucleolar rna hbii-52
WO2014130444A1 (en) * 2013-02-19 2014-08-28 Genomic Health, Inc. Method of predicting breast cancer prognosis
BR112016005225B1 (pt) * 2013-09-11 2023-11-14 Bio Theranostics, Inc Métodos para avaliar câncer de mama em um indivíduo
WO2015066068A1 (en) * 2013-10-29 2015-05-07 Genomic Health, Inc. Methods of incorporation of transcript chromosomal locus information for identification of biomarkers of disease recurrence risk
CN105214077B (zh) * 2014-06-03 2019-02-05 浙江阿思科力生物科技有限公司 Usp33在肿瘤中的应用
WO2016094330A2 (en) * 2014-12-08 2016-06-16 20/20 Genesystems, Inc Methods and machine learning systems for predicting the liklihood or risk of having cancer
CN107111689B (zh) * 2014-12-10 2021-12-07 皇家飞利浦有限公司 用于生成非编码-编码基因共表达网络的方法和系统
ES2887201T3 (es) 2015-09-01 2021-12-22 Eisai R&D Man Co Ltd Variantes de empalme asociadas con mutantes neomórficos de SF3B1
WO2017070581A1 (en) * 2015-10-23 2017-04-27 Novartis Ag Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
US11530448B2 (en) 2015-11-13 2022-12-20 Biotheranostics, Inc. Integration of tumor characteristics with breast cancer index
EP3202913B1 (en) * 2016-02-08 2019-01-30 King Faisal Specialist Hospital And Research Centre A set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival
US12006553B2 (en) * 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
EP3802816A4 (en) * 2018-06-08 2022-03-23 Glympse Bio, Inc. Activity sensor design
CN108893537B (zh) * 2018-07-19 2020-10-30 青岛泱深生物医药有限公司 C7orf70及其应用
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
US20220002815A1 (en) * 2018-11-04 2022-01-06 Pfs Genomics, Inc. Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy
CN109859801B (zh) * 2019-02-14 2023-09-19 辽宁省肿瘤医院 一种含有七个基因作为生物标志物预测肺鳞癌预后的模型及建立方法
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
WO2021216990A1 (en) * 2020-04-23 2021-10-28 Board Of Regents, The University Of Texas System Methods and compositions related to full-length excised intron rnas (flexi rnas)
CA3194956A1 (en) 2020-09-11 2022-03-17 Glympse Bio, Inc. Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
RU2763839C1 (ru) * 2021-04-27 2022-01-11 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Петрова" Минздрава России) Способ многофакторного прогноза рака молочной железы
CN113667749A (zh) * 2021-08-03 2021-11-19 广东省人民医院 四个关键基因组合评估乳腺癌风险的诊断试剂盒
CN114480650A (zh) * 2022-02-08 2022-05-13 深圳市陆为生物技术有限公司 一种预测三阴乳腺癌临床预后复发风险的标志物及模型
CN114657242B (zh) * 2022-03-16 2022-11-11 广州医科大学附属第一医院 Gpr33基因在马尔尼菲篮状菌易感人群评估的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081340B2 (en) * 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2005001138A2 (en) * 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
JP2005270093A (ja) * 2004-02-24 2005-10-06 Nippon Medical School 乳癌の術後予後予測に関与する遺伝子
US20080299550A1 (en) * 2004-09-20 2008-12-04 Bayer Healthcare Ag Methods and Kits For the Prediction of Therapeutic Success and Recurrence Free Survival In Cancer Therapy
US20100105564A1 (en) * 2006-09-15 2010-04-29 Mcgill University Stroma Derived Predictor of Breast Cancer
EP2094719A4 (en) * 2006-12-19 2010-01-06 Genego Inc NEW PROCEDURES FOR THE FUNCTIONAL ANALYSIS OF EXPERIMENTAL HIGH-PERFORMANCE DATA AND IDENTIFIED GENDER GROUPS THEREOF
EP2036988A1 (en) * 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2009071655A2 (en) * 2007-12-06 2009-06-11 Siemens Healthcare Diagnostics Inc. Methods for breast cancer prognosis
US20110020370A1 (en) * 2008-12-11 2011-01-27 Elias Georges Slc7a5 directed diagnostics and therapeutics for neoplastic disease
CN101851611A (zh) * 2009-04-01 2010-10-06 天津医科大学附属肿瘤医院 驱动蛋白样蛋白kif1b的转移相关功能和预测肿瘤患者预后的标志物用途及其应用方法
WO2010127399A1 (en) * 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Gene expression profiles and uses thereof
US20120309640A1 (en) * 2009-10-08 2012-12-06 Torti Frank M Diagnostic and Prognostic Markers for Cancer
CA2776751C (en) * 2009-11-23 2019-07-02 Genomic Health, Inc. Methods to predict clinical outcome of cancer
JP2013512000A (ja) * 2009-12-01 2013-04-11 コンペンディア バイオサイエンス, インコーポレイテッド 癌の分類
GB0922437D0 (en) * 2009-12-22 2010-02-03 Cancer Rec Tech Ltd Hypoxia tumour markers
US20130143753A1 (en) * 2010-03-01 2013-06-06 Adelbio Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
JP5940517B2 (ja) * 2010-03-31 2016-06-29 ジヴィドン ダイアグノスティックス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内分泌治療下における乳癌再発を予測するための方法

Also Published As

Publication number Publication date
SG11201402042PA (en) 2014-06-27
AU2012336120A1 (en) 2014-05-29
EP2776830A1 (en) 2014-09-17
CA2854805C (en) 2021-04-27
HK1201329A1 (en) 2015-08-28
CA2854805A1 (en) 2013-05-16
IL276488B (en) 2021-04-29
WO2013070521A1 (en) 2013-05-16
IL232445A0 (en) 2014-06-30
US20160222463A1 (en) 2016-08-04
NZ624700A (en) 2016-08-26
JP6147755B2 (ja) 2017-06-14
SG10202010758SA (en) 2020-11-27
US20190256923A1 (en) 2019-08-22
EP2776830A4 (en) 2015-07-15
EP2776830B1 (en) 2018-05-09
JP2014532428A (ja) 2014-12-08
MX2014005547A (es) 2014-08-29
US20140296085A1 (en) 2014-10-02
JP2017055769A (ja) 2017-03-23
IL232445B (en) 2018-10-31
US20200263257A1 (en) 2020-08-20
AU2012336120B2 (en) 2017-10-26
IL261708A (en) 2018-10-31
IL276488A (en) 2020-09-30
IL265136B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MX357402B (es) Metodo para predecir el pronostico de cancer de mama.
Cheng et al. Biomarkers in bladder cancer: translational and clinical implications
MX2013003077A (es) Diagnostico de cancer de mama.
MX2016004557A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
ES2721639T3 (es) Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
MX2016003245A (es) Calreticulina mutante para la diagnosis de malignidades mieloides.
BR112013004673A8 (pt) biomarcadores e métodos de tratamento.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
BR112014025269A2 (pt) método para o prognóstico e tratamento de metástase de câncer
ES2587591T3 (es) Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
WO2012109632A3 (en) Crown-like structures as a biomarker for cancer risk and cancer prognosis
MX336675B (es) Cribado para compuestos anticancerigenos utilizando actividad de netrina-1.
WO2011094759A3 (en) Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
PE20170298A1 (es) Composiciones y metodos relacionados con el diagnostico del cancer de prostata
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
MX2015002749A (es) Metodo diagnostico y terapeutico para el cancer dirigido a moleculas expresadas en celulas madre cancerosas.
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
Zhao et al. MicroRNA-588 is upregulated in human prostate cancer with prognostic and functional implications
WO2012166700A3 (en) Molecular profiling of a lethal tumor microenvironment
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies

Legal Events

Date Code Title Description
FG Grant or registration